NCT06696131

Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (estimated)
• Sponsor: Gaurav Gupta, MD · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The overall purpose of this study is to look at the safety and effectiveness of administering Tenecteplase (TNK) into the brain bleed (hematoma) instead of another clot-dissolving drug known as recombinant tissue plasminogen activator (rtPA), which is the current standard practice. Clot dissolving (Fibrinolytic) drugs work to break down blood clots and have been found to improve health outcomes when applied directly into the hematoma within the brain. Patients who take part in this study will undergo the same surgical procedure that would normally be performed to treat them, but with the exception of TNK not rtPA.

Conditions

• Intracerebral Hemorrhage
• Intracranial Hemorrhages
• Hemorrhagic Strokes

Interventions

Type	Name	Description
DRUG	TNK	TNK will be delivered into the site of the intracerebral hemorrhage via a brain catheter.

Timeline

• Start date: 2025-09-15
• Primary completion: 2027-01-15
• Completion: 2027-12-31
• First posted: 2024-11-20
• Last updated: 2025-04-23

Regulatory

• FDA-regulated drug study